Integra LifeSciences Holdings Corporation (IART) Focuses on Supply Chain Recovery and Growth Strategy

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Integra LifeSciences Holdings Corporation is among them.

Integra LifeSciences Holdings Corporation (NASDAQ:IART), based in Princeton, New Jersey, is a medical device company specializing in neurosurgery, wound care, otolaryngology, and tissue technologies. Its two main segments, Codman Specialty Surgical and Tissue Technologies, provide neurosurgical instruments and advanced wound care solutions to hospitals and specialty clinics globally.

In Q2 2025, Integra LifeSciences Holdings Corporation (NASDAQ:IART) reported flat sales of $415.61 million and a net loss of $484.07 million, reflecting operational challenges such as margin pressure, remediation efforts, and delayed product relaunches. Despite these hurdles, the corporation generated positive free cash flow of $44.97 million and updated its Q3 and full-year 2025 guidance, projecting modest single-digit revenue growth.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is focusing on operational transformation and supply chain recovery as part of its strategic shift to stabilize and grow revenue. For some investors, the company also falls into the category of overlooked stocks, as analysts view it as undervalued with a forward P/E ratio of 5.19–5.80 and potential upside of 12–26% from current levels, though market caution remains due to volatility and ongoing operational headwinds.

While we acknowledge the potential of IART as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.